FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	20540
wasnington,	D.C.	20049

STATEMENT	OF	CHANGES	IN BENEF	ICIAL	OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Pellini Michael J			2. Issuer Name and Ticker or Trading Symbol Singular Genomics Systems, Inc. [OMIC]					(Che	$ \begin{array}{ll} \text{5. Relationship of Reporting Person(s) to Issuer} \\ \text{(Check all applicable)} \\ X & \text{Director} \\ \end{array} $						
(Last)	`	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/29/2024					Officer (below)	give title	Othe belo	r (specify v)		
3010 SCIENCE PARK ROAD					4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	EGO C	A	92121)	_	•	Reporting Perethan One Re	
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication										
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						ed to satisfy				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			2. Transac Date (Month/Da	Execution Date,		Code (Instr.				4 and 5) Securities Beneficiall Owned Fo		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) o	r Price	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Conversion or Exercise (Instr. 3) 2. Conversion Date Execution Date (Month/Day/Year) Or Exercise Price of Derivative Security 3. Transaction Date Execution Date, if any (Month/Day/Year)		Cod	Transaction Code (Instr. 8) Acord		Derivative Expira		6. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number derivative Securities Beneficial Owned Following Reported Transactio	Owners Form: ly Direct (or Indir (I) (Inst	Beneficial Ownership ect (Instr. 4)		
				Cod	e V	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)	
Stock Option (Right to Buy)	\$0.372	05/29/2024		A		100,000		(1)	05/29/2034	Common Stock	100,000	\$0	100,00	0 D	

1. The option shares vest and become exercisable upon the earlier of the 2025 Annual Meeting of Stockholders or May 29, 2025.

/s/ Dalen Meeter, Attorney-in-

Fact

** Signature of Reporting Person

05/31/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.